PMID

Data

Article Title

Organization

Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.

University of Dundee

Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.

Janssen Research and Development

Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein Interactions?

University of Cambridge

A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.

Newcastle University

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.

East China Normal University

Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.

University of Bonn

E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.

Astrazeneca

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.

TBA

A comprehensive review of BET-targeting PROTACs for cancer therapy.

Xinxiang Medical University

Drug Hunting at the Nexus of Medicinal Chemistry and Chemical Biology and the Discovery of Novel Therapeutic Modalities.

Novartis Institutes For Biomedical Research

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.

Second Military Medical University

Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders.

Peking University

Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins.

University of Dundee

Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.

University of California Santa Cruz

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.

Janssen Research & Development

Understanding and Improving the Membrane Permeability of VH032-Based PROTACs.

University of California Santa Cruz

Solution Conformations Shed Light on PROTAC Cell Permeability.

Uppsala University

Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.

Genentech

Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications.

China Pharmaceutical University

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.

Shaoxing University

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Benevolentbio

OXOPYRROLIDINE UREA FPR2 AGONISTS

Bristol-Myers Squibb

Protease inhibitors

Medivir

Pyrazole compound

Sumitomo Dainippon Pharma

Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase

Translational Drug Development

Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them

Wisconsin Alumni Research Foundation

Structural elements of the gamma-aminobutyric acid type A receptor conferring subtype selectivity for benzodiazepine site ligands.

SynthÉLabo